Millions of people continue to experience symptoms months or years after recovering from an acute COVID-19 infection. Commonly referred to as Long COVID, or Post-Acute Sequelae of SARS-CoV-2 Infection (PASC), the condition encompasses a broad range of symptoms that can affect multiple organ systems.
Patients frequently report persistent fatigue, cognitive impairment, sleep disturbances, headaches, muscle pain, shortness of breath, anxiety, and changes in exercise tolerance. Researchers have proposed several mechanisms that may contribute to these symptoms, including immune dysregulation, persistent inflammatory responses, autonomic nervous system dysfunction, vascular abnormalities, and the presence of viral remnants that continue to stimulate the immune system.
Among these areas of investigation, inflammation and neuroinflammation have received considerable attention because they may help explain symptoms that extend beyond the respiratory system.
Inflammation and the Long COVID Puzzle
Inflammation is a normal part of the body's response to infection. In some Long COVID patients, however, evidence suggests that inflammatory processes may remain active long after the initial infection has resolved.
Researchers have identified immune system abnormalities and inflammatory markers in some patients with persistent symptoms. The extent to which these findings explain Long COVID remains an active area of research, but inflammation has become a recurring theme across multiple studies.
Neuroinflammation, or inflammation involving the nervous system, has received particular scrutiny because many Long COVID patients report symptoms such as brain fog, memory difficulties, headaches, and cognitive fatigue. Investigators continue to examine whether inflammatory changes in the brain and nervous system contribute to these experiences.
Why Cannabinoids Enter the Discussion
Interest in cannabinoids stems from their interaction with the endocannabinoid system, a biological network involved in regulating pain perception, sleep, mood, immune activity, and inflammatory signaling.
Cannabidiol (CBD) has become the most widely studied non-intoxicating cannabinoid. Laboratory and preclinical studies have demonstrated that CBD can influence inflammatory pathways and immune responses. Other cannabinoids, including cannabigerol (CBG), cannabichromene (CBC), and tetrahydrocannabivarin (THCV), are also under investigation for their effects on inflammation and neurological function.
These findings have led researchers to examine cannabinoids across a variety of conditions involving chronic pain, sleep disturbances, anxiety, and inflammatory processes. Many of those same symptom categories appear frequently among Long COVID patients.
The overlap has generated scientific interest, but it does not establish cannabinoids as a treatment for Long COVID. Evidence supporting cannabinoid use in Long COVID remains limited, and controlled clinical studies specifically targeting the condition are still relatively scarce.
Contributions from Dr. Staci Gruber and the MIND Program
One of the most recognized researchers in the field of medical cannabis is Dr. Staci Gruber, neuroscientist at Harvard Medical School and Director of the Marijuana Investigations for Neuroscientific Discovery (MIND) Program at McLean Hospital.
Established in 2014, the MIND Program was created to examine the effects of medical cannabis and cannabinoid-based therapies using objective scientific methods. The program's work has focused on cognition, brain function, sleep, pain, anxiety, quality of life, and clinical outcomes among patients using medical cannabis products.
The significance of this research lies in its emphasis on data collection and measurable outcomes. Much of the public conversation surrounding cannabis has historically been driven by personal experiences, political debate, or assumptions about the plant's effects. The MIND Program has sought to address questions that can only be answered through systematic observation and clinical research.
Published findings from MIND studies have documented improvements in several patient-reported outcome measures, including sleep quality, symptom burden, mood, and overall quality of life among certain groups of medical cannabis patients. The program has also investigated high-CBD formulations and their effects on anxiety-related conditions.
These studies were not designed to evaluate Long COVID. Their relevance comes from the symptom overlap between populations studied in cannabinoid research and populations affected by Long COVID. Sleep disruption, chronic pain, anxiety, cognitive complaints, and diminished quality of life are common themes in both.
Brain Fog and Cognitive Symptoms
Cognitive impairment remains one of the most commonly reported Long COVID symptoms. Patients often describe difficulties with concentration, memory recall, information processing, and mental stamina.
Researchers continue to investigate the biological mechanisms underlying these symptoms. Neuroinflammation has emerged as one area of interest because inflammatory activity within the nervous system can influence cognitive function.
Cannabinoids have been studied for their effects on neurological and inflammatory pathways, which has prompted discussion about whether they may warrant investigation in Long COVID populations. Existing evidence does not provide a clear answer. The available data support additional research rather than conclusions about effectiveness.
Current Limitations
Several factors limit what can currently be said about cannabinoids and Long COVID.
Many studies involving cannabinoids examine conditions other than Long COVID. Product formulations differ substantially between studies and commercial markets. Dosages, cannabinoid ratios, administration methods, and product quality vary considerably. These variables make direct comparisons difficult.
Long COVID itself presents additional challenges because symptoms vary widely between patients. A therapy that addresses one symptom cluster may have little effect on another.
Clinical trials designed specifically to evaluate cannabinoid interventions in Long COVID populations will be necessary to determine whether meaningful therapeutic benefits exist and, if so, which patient populations may benefit.
Conclusion
The scientific interest in cannabinoids and Long COVID originates from identifiable biological and clinical observations. Researchers studying Long COVID continue to investigate inflammation, neuroinflammation, pain pathways, sleep disturbances, and immune dysfunction. Cannabinoid research examines many of those same systems.
Work conducted by Dr. Staci Gruber and the MIND Program has contributed valuable data regarding how cannabinoid-based therapies may affect sleep, anxiety, cognition, symptom burden, and quality of life. Those findings provide context for ongoing discussions about Long COVID symptom management, even though they do not directly evaluate Long COVID itself.
At present, cannabinoids occupy a position familiar to many emerging therapies: supported by plausible biological mechanisms, informed by research in related conditions, and awaiting stronger evidence from studies designed to answer the specific clinical questions that Long COVID presents.